BeStock  
Stocks › Biotechnology › OBX

Obsidian Therapeutics OBX

US equityMarket cap rank #3397Biotechnology
$13.20 −$0.02 (-0.15%)
Pre-market · Oct 8, 8:20 am ET · After hours $13.20 0.00%
Open$13.02
Prev close$13.22
Day range$12.80 – $13.88
Volume359.0K
Market cap$815.40M
P/E (TTM)20.3
Dividend yield–

Fundamentals

Latest reported quarter: Q1, ended Mar 2026

Revenue$0.00
Operating profit-$20.28M+23.8% YoY
Net profit-$19.63M+21.4% YoY
Diluted EPS-$0.32+21.4% YoY
Free cash flow-$22.01M+9.9% YoY
Operating cash flow-$22.01M

Profitability & balance sheet

Return on assets-135.8%
Current ratio4.21
Liabilities / assets493.8%
Cash & investments$58.76M
Total debt$1.07M
Net cash (debt)$57.68M

Income statement

Line item 2026 Q1 2025 ANNUAL 2025 Q1 2024 ANNUAL
Total Operating Revenue $0.00 $0.00 $0.00 $0.00
Net Income to Parent Company -$19.63M -$100.61M -$24.99M -$83.11M
Net Income to Common Stockholders -$19.63M -$100.61M -$24.99M -$83.11M
Basic EPS -$0.32 -$1.63 -$0.41 -$1.35
Diluted EPS -$0.32 -$1.63 -$0.41 -$1.35
Profit from Continuing Operations -$19.63M -$100.61M -$24.99M -$83.11M
Net Profit -$19.63M -$100.61M -$24.99M -$83.11M
Operating Expense $20.28M $105.67M $26.60M $91.26M
Selling and Admin Expenses $4.55M $19.55M $5.48M $18.07M
-General & Admin Expense $4.55M $19.55M $5.48M $18.07M
Research & Development $15.73M $86.11M $21.13M $73.19M
Operating Profit -$20.28M -$105.67M -$26.60M -$91.26M
Net Non-Operating Interest Income (Expense) $647,000.00 $5.06M $1.62M $8.15M
Non-Operating Interest Income $647,000.00 $5.06M $1.62M $8.15M
Pretax Profit -$19.63M -$100.61M -$24.99M -$83.11M
Tax $0.00 $0.00 $0.00 $0.00

Balance sheet

Line item 2026 Q1 2025 ANNUAL 2024 ANNUAL
Gains/Losses Not Affecting Retained Earnings -$5,000.00 $23,000.00 -$27,000.00
Retained Earnings -$315.57M -$295.94M -$195.33M
-Common Stock $2,000.00 $1,000.00 $1,000.00
Capital Stock $2,000.00 $1,000.00 $1,000.00
Stockholders' Equity -$276.20M -$266.04M -$174.43M
Total Equity -$276.20M -$266.04M -$174.43M
Other Non-Current Liabilities $3,000.00 $3,000.00 $206,000.00
Convertible preferred securities $330.03M $338.03M $338.03M
Other Non-Current Assets $1.00M $1.00M $1.00M
-Gross PPE $5.09M $15.57M $17.89M
Net PPE $5.09M $6.06M $9.86M
Total Non-Current Assets $6.10M $7.06M $10.87M
Other Current Assets $5.28M $1.03M $4.58M
-Short Term Investments $32.32M $40.08M $118.51M
-Cash and Cash Equivalents $26.44M $40.41M $49.76M
Cash and Cash Equivalents & Short-Term Investments $58.76M $80.49M $168.27M
Total Current Assets $64.04M $81.52M $172.85M
Total Liabilities $346.33M $354.62M $358.14M
Total Current Liabilities $15.23M $15.36M $16.09M
-Long Term Capital Lease Obligation $1.07M $1.22M $3.82M
Long Term Debt and Capital Lease Obligation $1.07M $1.22M $3.82M
Total Non-Current Liabilities $331.11M $339.26M $342.06M
Other Current Liabilities $1.58M $1.42M $979,000.00
-Current Capital Lease Obligation $2.53M $3.06M $2.99M
Short-Term Debt and Capital Lease Obligation $2.53M $3.06M $2.99M
Current Accrued Expenses $8.75M $7.05M $4.74M
-Accounts Payable $738,000.00 $12,000.00 $1.82M
Payables $738,000.00 $12,000.00 $1.82M
Total Assets $70.14M $88.58M $183.71M
Additional Paid-In Capital $39.37M $29.87M $20.92M
-Accumulated Depreciation – -$9.51M -$8.03M

Cash flow

Line item 2026 Q1 2025 ANNUAL 2025 Q1 2024 ANNUAL
Free Cash Flow -$22.01M -$90.47M -$24.42M -$75.78M
Net cash flow from continuing operations -$22.01M -$90.39M -$24.37M -$75.00M
Beginning Cash Balance $41.41M $50.77M $50.77M $17.13M
Depreciation & Depletion & Amortization $340,000.00 $1.48M $378,000.00 $1.53M
Other Non-Cash Items -$51,000.00 -$141,000.00 -$31,000.00 -$17,000.00
Change in Working Capital -$3.86M $2.56M -$965,000.00 $1.75M
-Change in Prepaid Assets -$4.25M $3.55M $2.23M -$2.73M
-Change in Payables and Accrued Expense $395,000.00 -$793,000.00 -$3.00M $4.29M
-Change in Other Current Liabilities $0.00 -$200,000.00 -$200,000.00 $200,000.00
Net cash flow from investing $8.00M $81.02M $13.50M -$53.87M
Proceeds from Stock Option Exercised $47,000.00 $20,000.00 $6,000.00 $2.55M
Net PPE Purchase and Sale $0.00 -$73,000.00 -$56,000.00 -$779,000.00
Net Investment Purchase and Sale $8.00M $81.09M $13.56M -$53.10M
Financing Cash Flow $47,000.00 $20,000.00 $6,000.00 $162.52M
Net Cash Flow from Continuing Financing Activities $47,000.00 $20,000.00 $6,000.00 $162.52M
Ending Cash Balance $27.44M $41.41M $39.91M $50.77M
Net Change in Cash -$13.97M -$9.36M -$10.86M $33.64M
Net Cash Flow from Continuing Investing Activities $8.00M $81.02M $13.50M -$53.87M
Operating Cash Flow -$22.01M -$90.39M -$24.37M -$75.00M
Net Income from Continuing Operations -$19.63M -$100.61M -$24.99M -$83.11M
Net Preferred Stock Issuance – $0.00 – $160.50M
Gain/Loss from Continuing Operations – -$3,000.00 – -$8,000.00
Net Other Financing Charges – – – -$532,000.00

Discussion

No comments yet — be the first to weigh in on OBX.

Leave a comment

Scroll to Top